NEW YORK, Dec. 9 (GenomeWeb News) - BioVision will evaluate clinical samples provided by Switzerland-based Novartis Pharmaceuticals as part of a service agreement, BioVision said today.
In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.
The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.
